SG11201809031XA - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- SG11201809031XA SG11201809031XA SG11201809031XA SG11201809031XA SG11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA SG 11201809031X A SG11201809031X A SG 11201809031XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cognitive function
- leucine
- acetyl
- pharmaceutically acceptable
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title abstract 4
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title abstract 3
- 229960000669 acetylleucine Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 230000037230 mobility Effects 0.000 abstract 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809031XA true SG11201809031XA (en) | 2018-11-29 |
Family
ID=58633040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106190RA SG10202106190RA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| SG11201809031XA SG11201809031XA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106190RA SG10202106190RA (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10905670B2 (ko) |
| EP (1) | EP3445351B1 (ko) |
| JP (3) | JP7387264B2 (ko) |
| KR (4) | KR20240018683A (ko) |
| CN (2) | CN109069463B (ko) |
| AU (2) | AU2017252507B2 (ko) |
| BR (1) | BR112018071547A2 (ko) |
| CA (1) | CA3021155A1 (ko) |
| IL (3) | IL310508A (ko) |
| MX (2) | MX2018012739A (ko) |
| RU (2) | RU2021107001A (ko) |
| SG (2) | SG10202106190RA (ko) |
| WO (1) | WO2017182802A1 (ko) |
| ZA (1) | ZA201806849B (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202106190RA (en) * | 2016-04-19 | 2021-07-29 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| BR112021010923A2 (pt) * | 2018-12-06 | 2021-08-24 | Intrabio Ltd | Análogos deuterados de acetileucina |
| SG11202109512SA (en) * | 2019-03-02 | 2021-09-29 | Intrabio Ltd | Leucine, acetyl leucine, and related analogs for treating disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| SG10202106190RA (en) * | 2016-04-19 | 2021-07-29 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| EP3697406A1 (en) * | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 MX MX2018012739A patent/MX2018012739A/es unknown
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 KR KR1020247003393A patent/KR20240018683A/ko active Application Filing
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active IP Right Grant
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 RU RU2021107001A patent/RU2021107001A/ru unknown
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en active Application Filing
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active IP Right Grant
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active IP Right Cessation
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en active Pending
-
2023
- 2023-07-10 US US18/349,221 patent/US20230346732A1/en active Pending
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901125TA (en) | Treatment of dementia | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201809501PA (en) | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |